Hepatocyte growth factor (HGF) and its tyrosine kinase receptor Met play a pivotal role in the tumor metastatic phenotype and represent attractive therapeutic targets. We investigated the biochemical and biological effects of the tyrosine kinase inhibitor RPI-1 on the human lung cancer cell lines H460 and N592, which express constitutively active Met. RPI-1-treated cells showed downregulation of Met activation and expression, inhibition of HGF/Met-dependent downstream signaling involving AKT, signal transducers and activators of transcription 3 and paxillin, as well as a reduced expression of the proangiogenic factors vascular endothelial growth factor and basic fibroblast growth factor. Cell growth in soft agar of H460 cells was strongly reduced in the presence of the drug. Furthermore, RPI-1 inhibited both spontaneous and HGFinduced motility/invasiveness of both H460 and human endothelial cells. Targeting of Met signaling by alternative methods (Met small interfering RNA and anti-phosphorylated Met antibody intracellular transfer) produced comparable biochemical and biological effects. Using the spontaneously metastasizing lung carcinoma xenograft H460, daily oral treatment with well-tolerated doses of RPI-1 produced a significant reduction of spontaneous lung metastases (À75%; P < 0.001, compared with control mice). In addition, a significant inhibition of angiogenesis in primary s.c. tumors of treated mice was observed, possibly contributing to limit the development of metastases. The results provide preclinical evidence in support of Met targeting pharmacologic approach as a new option for the control of tumor metastatic dissemination. [Mol Cancer Ther 2006;5(9):2388 -97] 
Introduction
Met tyrosine kinase represents the high-affinity receptor for hepatocyte growth factor (HGF), also known as scatter factor, expressed predominantly in epithelial and endothelial cells. The HGF/Met-mediated signaling is involved in physiologic processes, such as epithelial cell dissociation (scattering), invasion, branching morphogenesis, and angiogenesis (1, 2) . Met receptor displays a heterodimeric structure consisting of an entirely extracellular 50-kDa a-subunit and a membrane-spanning 140-kDa h-subunit that are linked by disulfide bonds. The interaction of HGF with Met stimulates the tyrosine kinase activity of the receptor h-subunit, leading to autophosphorylation of specific tyrosine residues within the intracellular region. Such event further enhances the receptor enzymatic activity and allows the recruitment and phosphorylation of downstream signaling molecules and adaptor proteins. The phosphorylative events, in turn, lead to the activation of several signaling cascades, which regulate cell proliferation, survival, and cytoskeleton functions (3, 4) .
Met activity can be deregulated through different mechanisms in human tumors, such as gene amplification, mutation, or involvement in HGF-dependent autocrine loops (5) . The identification of germ-line missense mutations in the majority of hereditary papillary renal cell carcinomas provided an unequivocal evidence implying Met directly in tumorigenesis (6) . Met is frequently overexpressed in human cancers (7) . Moreover, recently, it has been shown that under hypoxic conditions, often present in solid tumors, Met is up-regulated and HGF/Metdependent signaling is amplified (8) . The overexpression or misexpression of HGF and/or Met has been correlated with poor prognosis in different tumor types, including lung cancer (5, 9, 10) . Indeed, HGF and Met represent the main mediators of the ''invasive growth,'' an integrated set of cellular responses, including survival, proliferation, cellcell dissociation, migration, and matrix degradation. Such a complex program, occurring physiologically during organ development and regeneration, becomes instrumental in tumor invasion and metastasis (11) . In addition, Met activation has been implicated in the regulation of tumor neovascularization. This function, which is probably achieved through the coordination of different mechanisms promoting endothelial cell growth, motility, and invasion, involves both a direct HGF stimulation of Met expressed on endothelial cells (12, 13) and an indirect regulation of paracrine angiogenic factors expressed by tumor cells (14, 15) . Together, these observations suggest that inappropriate Met signaling may be crucial in cancer progression, thus representing an attractive therapeutic target.
We recently described the activity of the 2-indolinone RPI-1 as an inhibitor of Ret tyrosine kinase oncoproteins in human thyroid carcinoma cells and tumor xenografts expressing a RET oncogene mutant (16 -18) . The effects of RPI-1 on other tyrosine kinase targets and tumor models remain to be investigated in detail. In the present study, we have explored the biochemical and cellular effects of RPI-1 in two human lung carcinoma cell lines expressing a constitutively active Met receptor. In addition, taking advantage of the ability of the H460 non -small cell lung cancer (NSCLC) to develop spontaneous lung metastases in mice (19) , the antimetastatic activity of RPI-1 was investigated also in vivo. The results indicate Met as an additional target of RPI-1 and support the interest for a pharmacologic approach aimed to target HGF/Met-dependent metastatic spreading.
Materials and Methods
Cell Culture and Drug Treatment Conditions. The human NSCLC cell line NCI-H460 and the SCLC cell line NCI-N592 (hereafter named H460 and N592, respectively) were kindly provided by Dr. A.F. Gazdar (University of Texas Southwestern Medical Center, Dallas, TX). Cells were maintained routinely in RPMI 1640 (BioWhittaker, Verviers, Belgium) supplemented with 10% fetal bovine serum. The human umbilical vascular endothelial cell (HUVEC) was routinely grown on BD BioCoat Matrigel Cellware (BD Biosciences, Bedford, MA) in Clonetics endothelial cell basal medium (Cambrex BioScience, Walkersville, MD) added with 10% fetal bovine serum and endothelial cell growth supplements provided by Cambrex BioScience. HUVECs from passages 6 to 9 were used for experiments.
The synthesis and the chemical structure of RPI-1 [1,3-dihydro-5,6-dimethoxy-3-[(4-hydroxyphenyl)methylene]-H-indol-2-one], formerly Cpd1, were reported previously (20) . The drug was dissolved in DMSO and further diluted in cell culture medium (final solvent concentration 0.5% even in control samples).
The anchorage-independent growth assay in soft agar was done as described previously (20) . The size and the number of colonies were determined by ImageMaster TotalLab version 1.10 (Amersham Biosciences, Little Chalfont, United Kingdom) analyzing digital images captured by ImageMaster VDS (Amersham Biosciences).
For biochemical analysis of HGF-induced effects, cells were serum starved for 24 hours, treated with RPI-1 for 18 hours, and then stimulated with HGF (20 ng/mL) for 10 minutes or 2 hours.
Antibody Intracellular Transfer. H460 cells were seeded at 4 Â 10 4 /cm 2 in six-well plates and, 24 hours later, subjected to protein delivery assay using PULSin (PolyPlus Transfection, Illkirch, France), a delivery reagent for the anti-phosphorylated Met (Tyr 1234 /Tyr 1235 ) antibody (Upstate Biotechnology, Lake Placid, NY) or the rabbit IgG (Sigma, St. Louis, MO), according to the manufacturer's instructions. Cells were washed twice with saline solution before addition of the PULSin/antibody mixture. After 4 hours of incubation at 37jC, the antibody solution was removed and replaced with fresh complete medium. Cells were used for invasion assay 24 hours later.
Cell Migration and Invasion Assays. H460 cells or HUVECs were seeded in complete medium and treated with different concentrations of RPI-1 for 24 hours. Then, cells were harvested and transferred to 24-well Transwell chambers (Costar, Corning, Inc., Corning, NY) in serumfree medium.
For the migration assay, 1.2 Â 10 5 cells per well were seeded in the upper Transwell chamber. The drug was added, at the same concentration used for the treatment, in both the upper and the lower chambers. HGF (20 and 30 ng/mL for H460 cells and HUVECs, respectively) was added in the lower chamber to assess HGF-induced migration. After 4 hours of incubation at 37jC, migrated cells were fixed in 95% ethanol, stained with a solution of 2% crystal violet in 70% ethanol, and counted under an inverted microscope.
For the invasion assay, the Transwell membranes were coated with 12.5 Ag Matrigel per well (BD Biosciences, San Jose, CA) and dried for 1 hour. Cells, treated as described above, were transferred (2.4 Â 10 5 per well) onto the artificial basement membrane. RPI-1 and HGF were added as indicated above. After 24 hours of incubation at 37jC, cells that invaded the Matrigel and migrated to the lower chamber were stained and counted as above.
ELISA. H460 cells were seeded at 2 Â 10 4 /cm 2 in complete medium and cultured for 2 days before serum starvation and treatment with solvent or RPI-1 for the indicated times. Then, conditioned media were harvested and clarified by centrifugation at 13,000 rpm for 15 minutes. Cells were trypsinized and counted. Supernatant aliquots were used for vascular endothelial growth factor (VEGF) protein determination with the human VEGF immunoassay kit from Biosource International (Camarillo, CA) according to the manufacturer's instructions. VEGF values were reported as pg/mL/10 6 cells. RNA Interference. A pool of four c-Met-specific 21-nucleotides forming a 19-bp duplex core with 2-nucleotide 3 ¶ overhangs was used to induce c-Met silencing, and a nonspecific control pool of small interfering RNA duplexes was used as negative control (Upstate Biotechnology). The oligonucleotides (100 nmol/L final concentration) were transfected into N592 cells using the siIMPORTER reagent (Upstate Biotechnology) according to the manufacturer's instructions. Cells were incubated for 120 hours before the preparation of cell lysates.
Immunoprecipitation and Immunoblot Analysis. Cells or tumor samples were processed for immunoprecipitation or total protein extraction and analyzed by immunoblotting as described previously (17) . Tumor protein lysates were prepared from frozen tumor samples pulverized by the The densitometric analysis of blots was done using ImageMaster TotalLab version 1.10.
In vivo Studies Animals. All experiments were carried out using 8-to 11-week-old female athymic nude CD-1 mice (Charles River, Calco, Italy). Mice were maintained in laminar flow rooms with constant temperature and humidity. Experimental protocols were approved by the Ethics Committee for Animal Experimentation of the Istituto Nazionale Tumori (Milan, Italy) according to the United Kingdom Coordinating Committee on Cancer Research Guidelines (21) .
RPI-1 Formulation and Delivery. We reported previously the procedure to formulate RPI-1 at a maximum concentration of 5 mg/mL polysorbate 80 (20% of final volume) and a cold solution of 10% ethanol in distilled water under stirring on ice (18) . The solution was administered by oral gavage at two dose levels (in a volume of 20 -30 mL/kg of mouse body weight), b.i.d., by a prolonged daily schedule. Control mice were treated in parallel with the vehicle (polysorbate 80/ethanol/distilled water, 20:8:72).
H460 Tumor Model System. H460 cells were injected i.p. into nude mice, adapted to grow as ascites, and maintained in vivo by i.p. passages (5 Â 10 6 per mouse in 0.5 mL PBS) as described previously (22) . The effects of RPI-1 on the growth of primary tumors and spontaneous lung metastases were tested in mice inoculated s.c. in the right flank with H460 ascitic tumor cells (2 Â 10 6 per mouse). Each control or drug-treated group included 9 to 11 mice. The growth of the s.c. tumor was followed by biweekly measurements of tumor diameters with a Vernier caliper. Tumor weight and tumor weight inhibition percentage in treated over control mice were calculated as reported previously (17) . Drug treatment was delivered by oral gavage for 45 days b.i.d. from day 0 at 100 and 150 mg/kg. At day 46, tumor-bearing mice were sacrificed by cervical dislocation and their lungs were removed. Lung lobes were spliced between two glass slides and the metastatic nodules were macroscopically counted against a bright light (19). Spontaneous lung metastases were present in 100% of control mice. Reading of metastases was done by two independent observers, with an interobserver reproducibility >95%. The metastatic nature of these areas was confirmed by histologic analysis of digital images obtained by Image Analysis System software (Delta System, Rome, Italy).
To induce experimental lung metastases, mice (12 per group) were injected i.v. with ascitic H460 cells (2 Â 10 6 per mouse; ref. 23 ) and then treated with RPI-1 (100 mg/kg) b.i.d. for 42 days starting 1 hour after cell injection (day 0). At day 43, all mice were sacrificed for lung observation as described above. In the presence of confluent metastatic nodules, lungs were defined as tumor invaded and nodules were not counted. For ethical reasons, mice presenting signs of suffering were sacrificed before day 43.
For tumor angiogenesis determination, mice s.c. implanted with ascitic H460 tumor cells (four to five mice per group) were treated with RPI-1 at the dose of 150 mg/kg b.i.d. for 11 days starting the same day of cell inoculum. Six hours after the last treatment, mice were sacrificed and their tumors were excised. Half of each tumor was fixed in formalin for standard H&E staining, and the other half was fixed in zinc fixative for immunohistochemical analysis of microvessel density (MVD) by detection of the endothelium-specific adhesion molecule CD31 as described previously (24) . Microvessels were quantified within six random fields at Â200 magnification (0.159 mm 2 /field) using the Image Analysis System software. Scoring of tumor sections was done by two independent observers, with an interobserver reproducibility >95%.
For in vivo pharmacodynamic studies, mice implanted s.c. with H460 tumors were treated with oral vehicle or RPI-1 at 150 mg/kg b.i.d. 5 days weekly for 2 weeks. Four hours after the last administration, two mice per group were sacrificed and the resected tumors were snap frozen in liquid nitrogen before immunoblot analysis of tumor protein lysates (see above).
Statistical Analysis. The Student's t test was used to determine the significance of in vitro data or to compare tumor weight or MVD in control and treated mice. The number of metastases in control and treated mice was compared by the Mann-Whitney test, whereas the frequency of tumor-invaded lungs was compared using the m 2 test.
Results
Inhibition of Met Tyrosine Phosphorylation and Expression in Human Lung Cancer Cell Lines. We first examined Met expression and activation in the N592 SCLC and H460 NSCLC cell lines. The two cell lines showed a different expression pattern of Met-related proteins, with the mature form of the protein (p140 Met ) highly overexpressed only in H460 cells (Fig. 1A) . Analysis of Met activation status in serum-starved cells showed that p140
Met was constitutively phosphorylated in both cell lines, whereas the high molecular weight form, described as an uncleaved Met precursor (25) , was phosphorylated only in N592 cells (Fig. 1B) . Then, we investigated the ability of RPI-1 to inhibit the Met kinase activity in the two cell lines following 24 hours of exposure ( Fig. 1C and D) . In N592 cells, RPI-1 induced a dose-dependent inhibition of tyrosine phosphorylation of both the p140
Met and the uncleaved protein evidenced by immunoprecipitation. In addition, the reduced phosphorylation was associated with a down-regulation of the Met proteins. In H460 cells, RPI-1 strongly inhibited tyrosine phosphorylation of the Met mature form at all concentrations tested (15 -60 Amol/L). The specific Met phosphorylation on Tyr 1234 /Tyr 1235 , known to activate the intrinsic kinase activity (3), was also examined in whole-cell lysates. A dose-dependent inhibition of Met phosphorylation was confirmed in both cell lines being evident around a drug concentration of 7.5 Amol/L. Nevertheless, differently from N592 cells, in H460 cells the overall Met expression was not affected by 24 hours of treatment with RPI-1.
Inhibition of HGF-Induced Met Activation and Downstream Events in H460 Cells. To investigate RPI-1 effects on HGF-dependent cellular events, the growth factor was added for 10 minutes or 2 hours to the medium of serumdeprived H460 cells exposed to different concentrations of RPI-1 for 18 hours (Fig. 2A) . HGF-induced Met tyrosine phosphorylation was inhibited by RPI-1 in a dosedependent way, and the inhibition was still evident 2 hours after the ligand addition. Similarly, HGF-induced activation of both AKT and STAT3 was inhibited even under conditions of marked activation of these Met signaling transducers (3). In such conditions, a weak drug-induced down-regulation of Met expression was also appreciable.
The biochemical effects of a prolonged exposure (72 hours) to RPI-1 were investigated in cells grown in complete medium. Figure 2B showed evidence of a marked druginduced inhibition of Met tyrosine phosphorylation. Such inhibitory effect was associated with receptor downregulation (not evidenced after 24 hours of treatment), indicating that, in the Met-overexpressing H460 cells, this event was delayed and required a prolonged drug exposure. A dose-dependent inhibition of AKT and STAT3 activation by RPI-1 was also observed. In addition, in the same experimental conditions, we observed inhibition of tyrosine phosphorylation of paxillin, a focal adhesion protein described previously as a target of Met signaling in lung cancer cells (26) .
Inhibition of Anchorage-Independent Cell Growth and Cell Motility/Invasion. Increased tumorigenicity, motility, and invasiveness have been described as biological consequences of HGF/Met deregulation in tumor cells (5) . In in vitro cell cultures, HGF/Met signaling has been reported to promote anchorage-independent growth, a feature associated with the malignant phenotype (27) . We thus examined the ability of H460 cells to form colonies in soft agar in the presence of RPI-1. Treatment with 20 Amol/L RPI-1, a concentration inhibiting Met activation (Fig. 1C  and D ) and H460 cell proliferation by f50% (IC 50 = 24.5 F 0.5 Amol/L, after 72 hours of treatment in a cell counting assay), resulted in a strong reduction of both colony number and size (Fig. 3) . Indeed, in RPI-1-treated samples, colony number was reduced by 80%, the largest colonies (>1,000 pixels) disappeared, the medium colonies (300 -1,000 pixels) were markedly reduced, and the small colonies (<300 pixels) represented 95% of the entire population. Similar results were obtained with N592 cells (data not shown).
Because Met activation plays a pivotal role in regulating cell motility and invasiveness of both tumor and endothelial cells (11, 12) , we investigated the effects of RPI-1 on these processes in either H460 cells or HUVECs. In migration and invasion assays, pretreatment of carcinoma cells (15 and 30 Amol/L) prevented HGF-induced migration and inhibited, in a dose-dependent way, both spontaneous and HGF-induced invasion (Fig. 4A) . The In vivo Antimetastatic Activity of RPI-1. To determine whether the inhibitory activity of RPI-1 on in vitro HGF/ Met-dependent processes was reflected in in vivo reduction of tumor cell invasiveness, we examined the drug effect on the occurrence of spontaneous lung metastases in mice implanted s.c. with H460 cells, which are endowed with metastatic ability in nude mice (19) . Two dose levels of RPI-1 were investigated (100 and 150 mg/kg) and delivered b.i.d. by oral gavage from days 0 to 45. The available model did not allow noninvasive assessment of therapeutic efficacy, and the use of bioluminescent imaging would be desirable in the future (28) . When mice were sacrificed for lung observation (day 46), in RPI-1-treated mice, the mean number of macroscopic metastases was significantly reduced versus controls at both tested doses (Table 1) . A clear dose-dependent effect was observed, with a reduction in the metastases number of 57% (P < 0.05) and 75% (P < 0.001) for the doses of 100 and 150 mg/kg, respectively. In Original magnification, Â100. Colony size distribution scored as percentage of small (<300 pixels), medium (300 -1,000 pixels), or large (>1,000 pixels) colonies. Columns, mean of two independent experiments; bars, SE. addition, one treated mouse (100 mg/kg) was metastasisfree when macroscopically inspected and showed evidence of small tumor nodules only at the histologic analysis. At the microscopic observation, H&E staining indicated that lungs of control mice were characterized by a high amount of neoplastic nodes (>100 neoplastic cells each node), whereas in lungs of RPI-1-treated mice only a moderate invasion, arranged in small nodules of neoplastic cells (<50 cells), was evident (Fig. 5A) . In contrast to the remarkable antimetastatic effect, the inhibitory activity of RPI-1 on the primary s.c. growing tumor was marginal (Table 1) and only a 31% of tumor weight inhibition (P > 0.05 versus control tumors) was achieved by the higher dose after 45 days of treatment, indicating that the strong inhibition of spontaneous lung metastases in treated mice could not be ascribed to a reduced primary tumor burden. Consistently, no linear relation was found (r = 0.5, by the Spearman rank correlation test) between s.c. tumor weight and number of spontaneous lung metastases (data not shown). The body weight loss values never exceeded 15% during the entire experimental frame, and lethal toxicity due to drug treatments was never observed.
To assess Met targeting in vivo, the receptor activation status was examined in tumor lysates. Immunoblot analysis showed a reduced Met autophosphorylation and, accordingly, a reduced activation of AKT in tumors derived from RPI-1-treated mice (150 mg/kg b.i.d. 5 days weekly for 2 weeks), thus confirming the drug pharmacodynamic activity (Fig. 5B) .
To get insight into the steps of the metastatic process affected by RPI-1, we examined the effects of the drug on artificial metastases (i.e., the tumor lung colonization induced by i.v. injection of H460 ascitic cells), thereby bypassing the first steps of the metastatic cascade. Mice were treated with oral RPI-1 (100 mg/kg b.i.d. for 42 days) and, the day after the last dose, sacrificed for lung observation. At this time, in the control group, 2 of 12 mice had already been euthanized and presented tumorinvaded lungs, 9 mice showed one or more lobes totally invaded by metastases, and only 1 mouse presented countable metastatic foci in all lung lobes. In the RPI-1-treated group, all mice were alive at the end of the experiment, 8 of 12 mice presented tumor-invaded lungs, and 4 mice (33% versus 8% in controls) presented countable metastatic areas. However, no statistical significance versus control mice was achieved (P > 0.2, by m 2 test), indicating a moderate effect of RPI-1 in this assay compared with the effect obtained on the spontaneous metastatic process. x Percentage of mice with metastases on total number of mice (9 mice in the solvent-treated group; 11 and 9 mice in the groups receiving 100 and 150 mg/kg RPI-1, respectively). k Mean number of metastatic nodules macroscopically counted in each lung. { Percentage of inhibition in treated over control mice. ** P < 0.05 versus controls, by Mann-Whitney test. To elucidate the cellular bases of such an effect, we examined in vitro the production of proangiogenic growth factors by tumor cells exposed to RPI-1. A reduced expression of two major endothelial growth factors, VEGF and bFGF, was observed in whole-cell extracts from RPI-1-treated H460 and N592 cells (Fig. 6B) . VEGF levels were then detected in the conditioned medium of H460 cells exposed to solvent or RPI-1 by an ELISA test. An increase in VEGF concentration in the medium from 24 to 48 hours of control cultures indicated the release of the angiogenic factor (Fig. 6C) . In the medium from treated cells, a significant dose-dependent reduction of VEGF was evidenced compared with the controls (33.5% and 50.4% of inhibition after exposure to 30 and 40 Amol/L RPI-1, respectively). In accordance to a previous report (30) , bFGF was barely detectable in the conditioned medium of H460 cells (data not shown).
Next, the RNA interference strategy (31) was used as an alternative method for disrupting Met signaling. Because this approach did not produce significant effects on Met expression in H460 cells (data not shown), the small interfering RNA methodology was applied to silence the receptor, expressed at a lower level, in the N592 cells (Fig. 6D) . A pool of four RNA duplexes specifically targeting Met mRNA caused the disappearance of the receptor precursor and an appreciable reduction of the mature form in N592 cells. Such selective Met silencing resulted in the abrogation of AKT activation and in an almost complete down-regulation of VEGF and bFGF expressions. These findings confirmed the regulatory role of Met on the two proangiogenic factors in this cell system and supported the specificity of RPI-1 effects as a consequence of Met signaling inhibition.
Discussion
In the present study, we showed that the small-molecule tyrosine kinase inhibitor RPI-1 inhibited Met activation and signaling in lung carcinoma cell lines both in vitro and in vivo. Indeed, oral treatment with RPI-1 resulted in a significant antimetastatic effect and inhibition of angiogenesis in the human H460 NSCLC xenograft. We showed that treatment with RPI-1 produced a marked and dose-dependent inhibition of spontaneous lung metastases in mice bearing s.c. growing H460 tumors. The reduction of tumor spreading could not be ascribed to the treatment effect on the primary tumor growth because only a marginal inhibition of the s.c. implanted tumor was achieved. Thus, the effect of RPI-1 on H460 tumor metastatic dissemination might reflect the inhibition of a predominant motogenic rather than proliferative/survival effect of HGF on tumor cells (32) . Accordingly, no evidence of apoptosis induction could be detected in in vitro -treated cells (data not shown). Furthermore, in our tumor model, RPI-1 was more effective against the formation of lung metastases spontaneously spreading from the s.c. tumor xenograft than against artificial metastases produced by lung colonization of cancer cells directly injected into the vascular flow. Metastases from solid tumors represent the final outcome of a multistep process that involves cellular and molecular mechanisms existing in tumor cells and in cells or components of tumor microenvironment (33) . Whereas spontaneous metastases occur only on completion of all steps of the process, artificial metastases do not need to overcome the barrier of the primary site microenvironment. Thus, it is likely that the remarkable inhibition of spontaneous lung metastasis formation might reflect a preferential drug effect on early steps of the metastatic cascade. Indeed, HGF and Met, as main mediators of in vivo ''invasive growth,'' actively participate to early steps by promoting critical events, such as dissociation of tumor cells at the primary site, invasion through the basement membrane and stroma, motility, angiogenesis, and interaction between tumor and endothelial cells (34) . Because microenvironment could affect the first steps of the process, the study in tumor models orthotopically growing might provide additional information on the therapeutic potential of the inhibitor. The results of our in vitro experiments indicated that biological functions relevant to the invasive/metastatic phenotype of lung cancer cells were impaired by RPI-1 treatment. In fact, in H460 cells, drug concentrations able to inhibit Met activation prevented HGF-induced cell migration and inhibited both spontaneous and HGFdependent invasion of Matrigel. Because migration through the artificial extracellular matrix depends on the cell ability to degrade the matrix and undergo chemotaxis, the inhibitory effect of RPI-1 in the cell invasion assay is likely relevant to its antimetastatic activity. The role of Met inhibition in the observed RPI-1 effects was supported by the similar effects obtained by targeting Met signaling in vitro with an antibody recognizing the activated Met. Furthermore, the inhibition of Met-mediated biological effects was consistent with the down-modulation of signaling pathways involving AKT, STAT3, and paxillin observed in RPI-1-treated cells. Indeed, although it cannot be ruled out the possibility that inhibition of additional tyrosine kinases might contribute to these effects, it is worth noting that paxillin and phosphatidylinositol 3-kinase, which lies upstream to AKT, have been implicated in cell migration and cytoskeleton functions regulated by Met (4, 35, 36) . In addition, our data show a marked inhibition of H460 cell anchorage-independent growth in soft agar, an in vitro feature of cancer cells that has been related to STAT3 activation through Met signaling (27) . Constitutive activation of Met in other NSCLC cells has been found to correlate with their ability of growing in the absence of anchorage, thus suggesting a role of the receptor in the promotion of cell survival in conditions where adhesion is lost, such as during dissemination from the primary tumor site (37) .
A further contribution to the reduced formation of spontaneous metastases in treated mice was possibly due to the drug inhibitory effect on the Met regulatory function Research. (33) . In fact, MVD was significantly decreased in s.c. growing H460 primary tumors of RPI-1-treated mice compared with control tumors. Such finding was not reflected in a substantial reduction of primary tumor growth, indicating that, in this model, the two events are not associated (38) . Similar effects were obtained on N592 xenograft growth and angiogenesis (data not shown). The inhibition of Met in endothelial cells could contribute to the reduction of MVD because HGF is a potent angiogenic factor acting directly on these cells (12, 13) . Accordingly, HGF-induced migration and invasion of HUVEC in in vitro assays was inhibited by RPI-1. In addition, our data showed a downregulation of VEGF and bFGF in H460 and N592 cells treated with the drug. These results suggest that RPI-1 might also affect the paracrine amplification of angiogenesis promoted by angiogenic factors produced by the tumor cells. Because VEGF expression is positively regulated by HGF/Met in different cell systems (14, 15) , the drug effect on VEGF was in keeping with the inhibition of Met signaling. Moreover, down-regulation of bFGF has been observed even in N592 cells where Met was silenced by RNA interference. These findings supported the interpretation that RPI-1-induced down-modulation of proangiogenic factors is a consequence of Met targeting.
In addition, to prevent Met tyrosine phosphorylation, RPI-1 induced a down-regulation of Met protein expression. Such an effect was also observed on Ret proteins (17, 18) . Further studies are needed to elucidate such RPI-1 property associated with protein tyrosine kinase inhibition, which is shared with other ATP-competitive inhibitors (39, 40) . The results of the present study suggest that Met down-regulation is dependent on the basal protein expression level because a prolonged exposure to the drug (72 versus 24 hours) was needed to observe a reduction in the highly overexpressing H460 cells compared with N592 cells. Nonetheless, on stimulation by exogenous HGF, the reduction of Met expression detectable in H460 cells even after 18 hours of RPI-1 treatment suggests that the drug could promote a mechanism involved in the physiologic ligand-induced receptor down-regulation (41) .
Different strategies have been developed to explore the therapeutic efficacy of targeting the HGF/Met regulatory system (2, 7, 42, 43) , although a clinically useful therapeutic option has yet to be found. In vitro anti-invasive activity and/or in vivo cytoreductive antitumor activity have been described by chemical Met inhibitors, including indolinone compounds (44 -49 ). An in vivo inhibitory effect against tumor dissemination and angiogenesis has been shown previously by peptide antagonists of HGF/Met delivered or not by a gene therapy approach (34, 50, 51) . The present study, by the use of a spontaneous lung-metastasizing human tumor model, provides evidence that a marked in vivo antimetastatic and antiangiogenic activity can be achieved even by a pharmacologic approach with a smallmolecule Met inhibitor. Thus, RPI-1, known as an inhibitor of Ret tyrosine kinases (16 -18, 20) , likely functions as a multitarget agent similarly to other in vivo effective tyrosine kinase inhibitors (52, 53) .
Collectively, the data presented in the study provide preclinical support to the view that Met targeting by a pharmacologic approach holds promise as an exploitable option in antimetastatic therapy of cancer.
